PetMed Express (PETS) Aktievy
PetMed Express, Inc. bedriver tillsammans med sina dotterbolag verksamhet som djurapotek i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 5/6 |
| Utdelningar | 0/6 |
PETS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PetMed Express, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$1.79 |
| 52 veckors högsta | US$4.10 |
| 52 veckors lägsta | US$1.57 |
| Beta | 0.77 |
| 1 månads förändring | -19.73% |
| 3 månaders förändring | -19.73% |
| 1 års förändring | -46.73% |
| 3 års förändring | -87.28% |
| 5 års förändring | -94.74% |
| Förändring sedan börsintroduktionen | 43.20% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jun 23
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.Uppdatering av berättelse • Jun 07
PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.Seeking Alpha • May 27
PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaRecent updates
Uppdatering av berättelse • Jun 23
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.Uppdatering av berättelse • Jun 07
PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.Seeking Alpha • May 27
PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaUppdatering av berättelse • May 23
PETS: Rural King Partnership Will Shape Future Margins And Earnings Outlook
Analysts have slightly reduced their price target on PetMed Express, attributing the change to a marginally lower discount rate and a modest increase in the assumed future P/E multiple as the main factors behind the revised outlook. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King’s retail stores and digital platforms, focusing on prescription medications, preventatives and broader pet health products (Key Developments).Uppdatering av berättelse • Apr 29
PETS: Rural King Partnership Will Shape Future Margins And Earnings Multiple
Analysts have trimmed their price target on PetMed Express to reflect a fair value update from $3.00 to $2.15 as they incorporate more moderate expectations for revenue contraction, profit margins, and a higher future P/E multiple into their models. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King retail stores and digital platforms, expanding access to prescription medications, preventatives and pet health products for Rural King customers (Key Developments).Analysartikel • Nov 13
Getting In Cheap On PetMed Express, Inc. (NASDAQ:PETS) Is Unlikely
It's not a stretch to say that PetMed Express, Inc.'s ( NASDAQ:PETS ) price-to-sales (or "P/S") ratio of 0.3x right now...Analysartikel • Apr 09
Some Confidence Is Lacking In PetMed Express, Inc. (NASDAQ:PETS) As Shares Slide 26%
To the annoyance of some shareholders, PetMed Express, Inc. ( NASDAQ:PETS ) shares are down a considerable 26% in the...
Ny berättelse • Apr 06
Cost Cuts And Digital Upgrades Will Strain Future Margins
Optimism regarding savings from PetCareRx integration could jeopardize future profitability if anticipated savings do not materialize.Seeking Alpha • Feb 10
PetMed Express: Dip Or Rip, A Buy After Earnings
Summary PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside. Even if it takes time to take shape, improvements in PetMed's operating performance could ultimately send the stock back to prices north of $15 per share. Read the full article on Seeking AlphaAnalysartikel • Feb 08
We Think PetMed Express (NASDAQ:PETS) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Analysartikel • Jan 09
Some PetMed Express, Inc. (NASDAQ:PETS) Shareholders Look For Exit As Shares Take 28% Pounding
PetMed Express, Inc. ( NASDAQ:PETS ) shares have retraced a considerable 28% in the last month, reversing a fair amount...Seeking Alpha • Nov 12
PetMed Express: Why (And Why Not) The Rebound Could Continue
Summary PetMed Express (PETS) surged 35.8% on Nov. 7, following the online pet pharmacy's latest quarterly earnings release. Despite the massive post-earnings surge, further upside may lie ahead, if the turnaround continues. PetMed's management team is implementing a strategy change, not just cost-cutting measures, to continue improving the company's fiscal performance. Although many risks and uncertainties remain, given the outsized impact further improvements could have on the PETS stock price, at the very least add it to your watchlist. Read the full article on Seeking AlphaAnalysartikel • Oct 04
Optimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking
PetMed Express, Inc. ( NASDAQ:PETS ) shares have had a really impressive month, gaining 28% after a shaky period...Analysartikel • Aug 09
PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
There's been a notable change in appetite for PetMed Express, Inc. ( NASDAQ:PETS ) shares in the week since its...Analysartikel • Jun 14
PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates
PetMed Express, Inc. ( NASDAQ:PETS ) last week reported its latest annual results, which makes it a good time for...Analysartikel • Jun 12
PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the Dividend Discount Model, PetMed Express fair value estimate is US$7.95 Current share price of...Analysartikel • Oct 09
A Look At The Fair Value Of PetMed Express, Inc. (NASDAQ:PETS)
Key Insights PetMed Express' estimated fair value is US$11.85 based on 2 Stage Free Cash Flow to Equity Current share...Analysartikel • Aug 07
PetMed Express (NASDAQ:PETS) Is Paying Out A Dividend Of $0.30
The board of PetMed Express, Inc. ( NASDAQ:PETS ) has announced that it will pay a dividend of $0.30 per share on the...Aktieägarnas avkastning
| PETS | US Specialty Retail | US Marknad | |
|---|---|---|---|
| 7D | 2.3% | 3.3% | -2.5% |
| 1Y | -46.7% | 8.7% | 20.1% |
Avkastning vs industri: PETS presterade sämre än US Specialty Retail branschen som gav 8.7 % under det senaste året.
Avkastning vs Marknaden: PETS presterade sämre än US marknaden som gav 20.1 % under det senaste året.
Prisvolatilitet
| PETS volatility | |
|---|---|
| PETS Average Weekly Movement | 7.0% |
| Specialty Retail Industry Average Movement | 7.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: PETS har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: PETS s veckovolatilitet har minskat från 14% till 7% under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1996 | 189 | Leslie C. Campbell | www.1800petmeds.com |
PetMed Express, Inc. bedriver tillsammans med sina dotterbolag verksamhet som apotek för sällskapsdjur i USA. Företaget marknadsför receptbelagda och receptfria läkemedel, hälsoprodukter och andra förnödenheter för hundar, katter och hästar. Företaget erbjuder receptfria läkemedel och tillbehör, t.ex. produkter mot loppor och fästingar, produkter för ben- och ledvård, vitaminer, godis, kosttillskott, hygienprodukter och hushållsartiklar för husdjur, samt receptbelagda läkemedel, t.ex. medel mot hjärtmask, loppor och fästingar, artrit, dermatit, sköldkörtel, diabetes, smärtstillande medel, hjärt-/blodtrycksmediciner och andra specialmediciner samt generiska substitut.
PetMed Express, Inc. Sammanfattning av grunderna
| PETS grundläggande statistik | |
|---|---|
| Börsvärde | US$37.64m |
| Vinst(TTM) | -US$57.29m |
| Intäkter(TTM) | US$179.02m |
0.2x
P/S-förhållande-0.7x
P/E-förhållandeÄr PETS övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| PETS resultaträkning (TTM) | |
|---|---|
| Intäkter | US$179.02m |
| Kostnad för intäkter | US$128.81m |
| Bruttovinst | US$50.22m |
| Övriga kostnader | US$107.50m |
| Intäkter | -US$57.29m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -2.72 |
| Bruttomarginal | 28.05% |
| Nettovinstmarginal | -32.00% |
| Skuld/egenkapitalförhållande | 0% |
Hur har PETS utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/06/25 03:54 |
| Aktiekurs vid dagens slut | 2026/06/24 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2026/03/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
PetMed Express, Inc. bevakas av 15 analytiker. 1 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Erin Wilson Wright | BofA Global Research |
| Kristine Koerber | Citizens JMP Securities, LLC |
| David Westenberg | CL King & Associates, Inc. |